2 citations
,
December 2013 in “Cancer Research” This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.
1 citations
,
June 2025 in “Supportive Care in Cancer” This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.
4 citations
,
December 2021 in “Journal of Clinical Nursing” This study observed that women with early-stage breast cancer often felt inadequately prepared for the discomfort and time commitments of scalp cooling during chemotherapy, leading to the development of patient-co-produced informational resources to better prepare them.
11 citations
,
August 2017 in “Supportive care in cancer” This study highlights the significant impact of eyebrow and eyelash loss during chemotherapy on women's quality of life, noting both emotional and physical challenges.
May 2015 in “Cancer research” This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.